Investigational Drug Information for EIDD-2801
✉ Email this page to a colleague
What is the development status for investigational drug EIDD-2801?
EIDD-2801 is an investigational drug.
There have been 6 clinical trials for EIDD-2801.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 16th 2020.
The most common disease conditions in clinical trials are COVID-19, Infection, and Communicable Diseases. The leading clinical trial sponsors are Ridgeback Biotherapeutics, LP, Merck Sharp & Dohme LLC, and Lancaster University.
Summary for EIDD-2801
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-06-16) |
| Vendors | 44 |
Recent Clinical Trials for EIDD-2801
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) | Merck Sharp & Dohme LLC | Phase 1 |
| A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) | Merck Sharp & Dohme LLC | Phase 1 |
| AGILE (Early Phase Platform Trial for COVID-19) | Lancaster University | Phase 1/Phase 2 |
Clinical Trial Summary for EIDD-2801
Top disease conditions for EIDD-2801
Top clinical trial sponsors for EIDD-2801
US Patents for EIDD-2801
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
